Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration Clinical Trial
Official title:
A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration
| Verified date | February 2017 |
| Source | Lawson Health Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Primary Objectives:
To assess the efficacy of intravitreal administered Eylea in preventing visual loss in
subjects with a retinal pigment epithelial detachment (PED) subtype of neovascular
age-related macular degeneration (AMD) measured by mean change in BCVA at Month 12 compared
to Baseline.
Secondary Objectives:
1. To assess the safety and tolerability of repeated intravitreal administration of Eylea
in subjects with the PED subtype of neovascular AMD for a period of 1 year
2. To assess the effect of repeated intravitreal administration of Eylea on Central
Subfield Thickness (CSFT), Central Subfield Volume (CSFV), and PED height and volume.
3. To assess the effect of repeated intravitreal administration of Eylea on vision related
quality of life in subjects with PED study type of neovascular AMD assessed using the
NEI/VFQ-25 questionnaire
| Status | Completed |
| Enrollment | 37 |
| Est. completion date | November 2016 |
| Est. primary completion date | November 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 50 Years and older |
| Eligibility |
Inclusion Criteria: 1. Signed, informed consent. 2. Men and women greater than or equal to 55 years of age. 3. Recent development of RPED secondary to AMD. 4. ETDRS best corrected visual acuities of 20/40 to 20/320 (letter score of 73 to 25) in the study eye. 5. Willing and committed and able to return for all clinic visits and complete all study related procedures. Exclusion Criteria: 1. Any prior treatment for neovascular AMD except dietary supplements or vitamins. (for patients in the treatment naïve group only) 2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye. 3. Total lesion size greater than 12 disc areas. 4. Subretinal hemorrhage that is either 50% or more of the total lesion area or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. 5. Scar or fibrosis making up greater than 50% of the total lesion in the study eye. 6. Scar, fibrosis or atrophy involving the center of the fovea. 7. Presence of a retinal pigment epithelial tear. 8. History of a vitreous hemorrhage within 4 weeks prior to initiation of the study. 9. Presence of other causes of choroidal neovascular membrane other than AMD. 10. History of clinical evidence of diabetic retinopathy, especially diabetic maculopathy or macular edema from other causes, including retinal vein occlusion or diabetes 11. Prior vitrectomy surgery in the study eye. 12. History of retinal detachment treatment in the study eye. 13. History of macular hole in the study eye. 14. Any intraocular/periocular surgery within 3 months of the initiation of the study. 15. Prior trabeculectomy or filtering surgery in the study eye. 16. Uncontrolled glaucoma, defined as a pressure greater than 25 mmHg despite treatment. 17. Active intraocular inflammation. 18. Active ocular/periocular infection. 19. Any history of uveitis. 20. Active scleritis or episcleritis. 21. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of YAG posterior capsulotomy) in the study eye. 22. Previous radiation therapy in the region of the study eye. 23. History of corneal transplant or corneal dystrophy in the study eye. 24. Significant medial opacities including cataract that may interfere with visual acuity or fundus photography. 25. Any disease or ocular condition which, in the opinion of the investigator could either increase in the risk to the subject beyond what is expected from a standard procedure of intraocular injections or which may be considered contraindicated for the use of the investigational drug (VEGF Trap). 26. The use of long acting steroids systemically or intraocularly. 27. Any history of allergy to Proviodine or fluorescein sodium. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Ivey Eye Institute | London | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Lawson Health Research Institute |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | efficacy of Eylea in patients with RPED | visual acuity mean change from baseline compared to month 12 | baseline to month 12 | |
| Secondary | safety and tolerability of repeated Eylea injection | assessment of adverse events at each visit | period of 1 year | |
| Secondary | effect of repeated Eylea injections of Central Subfield Thickness , Central Subfield Volume and PED height and volume | using OCT (optical coherence tomography) thickness, volume and height will be compared from baseline to month 12 | baseline to month 12 | |
| Secondary | effect of repeated Eyle injections on vision related quality of life | using the standardized NEI/VFQ-25 questionnaire reponses will be compared from baseline to month 12 | baseline to month 12 |